Department of Pharmacy Practice and Science, UNMC College of Pharmacy, Omaha, Nebraska, USA.
Midwestern University, College of Pharmacy Downers Grove Campus, Downers Grove, Illinois, USA.
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02629-20.
Augmented renal clearance (ARC) can occur in critically ill pediatric patients receiving aminoglycosides such as gentamicin and tobramycin, yet optimal dosing strategies for ARC are undefined. We evaluated the probability of achieving efficacious or toxic exposures in pediatrics. Parallel population modeling of concentration strategies were pursued using v1.5.2 (nonparametric) and Monolix v2019R2 (parametric). Bayesian exposures were used to classify ARC based on total clearance (CL). The effects of serum creatinine (SCR), creatinine clearance (CRCL), total body weight (TBW), postnatal age (PNA), and ARC were explored as covariates. The probabilities of target attainment (PTA) (i.e., maximum concentration []/MIC, area under the concentration-time curve [AUC]/MIC) and of toxic exposure (PTE) (i.e., minimum concentration [] > 2 μg/ml) were calculated according to PNA and ARC. A total of 123 patients (1 to 21 years old, 56% female) contributed 304 concentrations. A two-compartment model was superior to a one-compartment model in both approaches. Bayesian posterior predicted concentrations from the nonparametric base model fit the data well ( = 0.96) and classified 34 patients as having ARC (28%). Both the nonparametric and parametric approaches resulted in allometrically scaling of TBW on volume (V) and clearance (CL). ARC modified CL and central V. CRCL and a maturation function modified CL. ARC was associated with a 1.49- versus 1.66-fold increase in CL and a 1.56- versus 1.66-fold increase in the central V (nonparametric versus parametric). A high dose of 12 mg/kg of body weight/day was required to achieve adequate PTA when MICs were 1 to 2 μg/ml; ARC lowered achievable MICs. When PNA was <2 years, PTE was increased. Aminoglycoside monotherapy should be avoided in critically ill pediatric patients with ARC when MICs exceed 1 μg/ml, as optimal exposures are unachievable with standard dosing.
增强型肾清除率(ARC)可发生于接受氨基糖苷类药物(如庆大霉素和妥布霉素)治疗的危重症儿科患者中,但 ARC 的最佳给药策略尚未明确。我们评估了在儿科中实现有效或毒性暴露的概率。使用 v1.5.2(非参数)和 Monolix v2019R2(参数)并行进行浓度策略的群体建模。贝叶斯暴露用于根据总清除率(CL)对 ARC 进行分类。探索了血清肌酐(SCR)、肌酐清除率(CRCL)、总体重(TBW)、出生后年龄(PNA)和 ARC 作为协变量的影响。根据 PNA 和 ARC 计算了目标达成概率(PTA)(即最大浓度 []/MIC,浓度-时间曲线下面积 [AUC]/MIC)和毒性暴露概率(PTE)(即最小浓度 [] > 2μg/ml)。共纳入 123 例(1 至 21 岁,56%为女性)患者,共 304 个浓度。在这两种方法中,两室模型均优于一室模型。非参数基础模型的贝叶斯后验预测浓度与数据拟合良好( = 0.96),并将 34 例患者分类为 ARC(28%)。非参数和参数方法均导致 TBW 按体积(V)和清除率(CL)进行比例缩放。ARC 改变了 CL 和中央 V。CRCL 和成熟函数改变了 CL。ARC 与 CL 和中央 V 分别增加 1.49 倍和 1.56 倍(非参数与参数)相关。当 MIC 为 1 至 2μg/ml 时,需要 12mg/kg 体重/天的高剂量才能实现足够的 PTA;ARC 降低了可实现的 MIC。当 PNA <2 岁时,PTE 增加。当 MIC 超过 1μg/ml 时,应避免在 ARC 的危重症儿科患者中使用氨基糖苷类单药治疗,因为标准剂量无法实现最佳暴露。